Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries

Abstract

Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries,

The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy

“…Our results suggest that replacing PCV7 with PCV13 had a considerable impact on reducing the PD-related economic burden. Following the PCV7 era, the residual economic burden related to PD was substantial, and its replacement with PCV13 was associated with a decrease in annual PD-related costs [ 8 ]. A modelling study showed that, following the introduction of PCV7 in Europe, the direct medical costs attributed to IPD-causing serotypes contained in PCV7 were reduced from EUR 18.5 million to EUR 2.8 million [ 8 ].…”

“…Following the PCV7 era, the residual economic burden related to PD was substantial, and its replacement with PCV13 was associated with a decrease in annual PD-related costs [ 8 ]. A modelling study showed that, following the introduction of PCV7 in Europe, the direct medical costs attributed to IPD-causing serotypes contained in PCV7 were reduced from EUR 18.5 million to EUR 2.8 million [ 8 ]. While an increase in the direct medical costs attributed to serotypes unique to PCV13 was recorded in the PCV7 era, the subsequent replacement with PCV13 was associated with a substantial reduction of EUR 11.4 million to EUR 2.5 million [ 8 ].…”

“…The inclusion of PCV13 into the Veneto immunization schedule resulted in a decrease of 19.7% in the hospitalization of children < 4 years of age between 2011 and 2013 [ 7 ]. A Markov model determined that the introduction of PCV7 reduced IPD-related deaths from 129 to 19, from an estimated 4649 cases in the pre-PCV7 period; further reductions were seen following the introduction of PCV13 [ 8 ]. Between 2007 and 2014, there was a substantial reduction in the overall incidence of IPD (risk ratio [RR] = 0.4, 95% confidence interval [CI]: 0.3–0.5; p < 0.0001), especially in children < 5 years of age (RR = 0.3, 95% CI: 0.2–0.7; p = 0.0002) [ 9 ].…”

“…Assessing the residual and vaccine-preventable burden of PD following the inclusion of higher-valency PCVs into national immunization programs can help determine their potential value in reducing PD-related health and economic burden. PD is associated with substantial direct medical costs and indirect costs (related to reduced productivity in parents and caregivers) [ 4 , 8 , 11 ]. For example, a decision-tree-based model used to assess healthcare resource utilization (HCRU) in Europe estimated that the total direct medical costs attributed to IPD in the pre- and post-PCV13 era were EUR 15.0 million and EUR 4.5 million, respectively [ 8 ].…”

“…PD is associated with substantial direct medical costs and indirect costs (related to reduced productivity in parents and caregivers) [ 4 , 8 , 11 ]. For example, a decision-tree-based model used to assess healthcare resource utilization (HCRU) in Europe estimated that the total direct medical costs attributed to IPD in the pre- and post-PCV13 era were EUR 15.0 million and EUR 4.5 million, respectively [ 8 ]. In addition, the estimated direct medical costs per episode of IPD-related meningitis and bacteremia post-PCV7 introduction in Italy were EUR 8228 and EUR 10,874–11,789, respectively; in Spain, they were EUR 3239 and EUR 3786–4039, respectively [ 8 ].…”